TO THE EDITOR:
==============

The COVID-19 pandemic has resulted in nearly 7 million confirmed infections and \>400 000 deaths as of June 7, 2020, with 3 billion people under lockdown worldwide. Nucleic acid tests of the disease-causing SARS-CoV-2 have been the mainstream diagnostic method in the early phase of outbreak, but the abundance of virus is reported to fade 3--5 weeks after infection *(*[@jfaa100-B1]*)*. Furthermore, with growing concern about halted social activity and intention to reopen, serological assays detecting SARS-CoV-2 antibodies for population surveillance have gained increasing interest. To have reasonable expectations of the antibody tests, better understanding of their properties is warranted.

Key Proteins in SARS-CoV-2
==========================

SARS-CoV-2 is an enveloped, single-stranded, and positive-sense RNA virus that belongs to the family of Coronaviridae. It has 4 major structural proteins---spike (S), envelope, membrane, and nucleocapsid (N)---and a number of other nonstructural proteins. The S protein is essential to viral attachment, fusion, entry, and transmission. Its N-terminal S1 subunit, composed of N-terminal domain and receptor-binding domain (RBD), is responsible for virus--receptor binding, and the C-terminal S2 subunit is responsible for virus--cell membrane fusion. The S1-RBD interacts with host cells expressing angiotensin-converting enzyme 2 as receptors. The receptor binding triggers conformational changes in the S2 subunit that result in virus fusion and entry into the target cell *(*[@jfaa100-B2]*)*.

Humoral Response to SARS-CoV-2
==============================

The time course of SARS-CoV-2 seroconversion is not fully understood at this time, but studies are rapidly emerging. The seroconversion window may range from a few days to 3 weeks after symptom onset *(*[@jfaa100-B3]*)*. The median duration of the IgM and IgA detection period was reported to be 5 days, whereas IgG was detected at a median of 14 days after symptom onset *(*[@jfaa100-B4]*)*. Within 2 weeks after symptom onset, the positive rate of total antibody usually increased to nearly 100%.

Format of Serological Antibody Tests
====================================

The development of antibody tests starts from selecting antigen epitopes in the viral protein to allow antibodies (IgM, IgA, IgG) present in infected individuals to bind to recombinant viral proteins. S protein tends to be the a more desirable target given its specificity and high immunogenicity, with the RBD in S protein being the target of many neutralizing antibodies; however, other strategies use both S and N proteins. Several formats of antibody assays for SARS-CoV-2 have been produced, including qualitative lateral flow assay, qualitative or quantitative ELISA, or chemiluminescent assay and neutralizing assays. The first 2 types test for either total antibodies or for specific IgG, IgM, or IgA antibodies. Neutralizing assays test for active antibodies that can effectively block the virus. The antibody assay also needs to demonstrate minimal cross-reactivity with other coronaviruses *(*[@jfaa100-B2]*)*.

As of June 7, 2020, the US Food and Drug Administration has issued emergency use authorizations for 17 serological tests, and we summarized their technical features in [Table 1](#jfaa100-T1){ref-type="table"}. The Vitros assay, for example, uses a SARS-CoV-2 S protein antigen to immobilize antibodies in the blood sample and murine monoclonal antihuman IgM/IgG antibodies for detection. The Diasorin assay uses recombinant S1 and S2 antigens to capture sample antibodies on the solid-phase, and mouse monoclonal antibodies to human IgG for detection. The majority of the assays claimed positive agreement with PCR between 80% and 90% and close to 100% negative agreement.

###### 

Antibody assays with US Food and Drug Administration emergency use authorizations as of June 7, 2020.

  Test name                                                             Manufacturer                                             Approval date  Format                                                   Antigen target                              Antibody class(es)
  --------------------------------------------------------------------- ------------------------------------------------------- --------------- -------------------------------------------------------- ------------------------------------------- --------------------
  qSARS-CoV-2 IgG/IgM Rapid Test                                        Cellex                                                     4/1/2020     Lateral flow immunoassay                                 SARS-CoV-2 S and N proteins                 IgM, IgG
  DPP COVID-19 IgM/IgG                                                  Chembio Diagnostic System                                  4/14/2020    Lateral flow with reader                                 SARS-CoV-2 N protein                        IgM, IgG
  VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack   Ortho Clinical Diagnostics                                 4/14/2020    Qualitative chemiluminescent assay                       SARS-CoV-2 S protein                        Total Antibody
  COVID-19 ELISA IgG Antibody Test                                      Mount Sinai Laboratory                                     4/15/2020    Antibody-titer ELISA                                     SARS-CoV-2 S protein and RBD protein        IgG
  Anti-SARS-CoV-2 Rapid Test                                            Autobio Diagnostics                                        4/24/2020    Lateral flow immunoassay                                 SARS-CoV-2 S protein                        IgM, IgG
  VITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent Pack     Ortho Clinical Diagnostics                                 4/24/2020    Qualitative chemiluminescent assay                       SARS-CoV-2 S protein                        IgG
  LIAISON SARS-CoV-2 S1/S2 IgG                                          DiaSorin                                                   4/24/2020    Qualitative chemiluminescent microparticle immunoassay   SARS-CoV-2 S1 and S2 proteins               IgG
  SARS-CoV-2 IgG assay                                                  Abbott Laboratories                                        4/26/2020    Qualitative chemiluminescent microparticle immunoassay   SARS-CoV-2 N protein                        IgG
  Platelia SARS-CoV-2 Total Ab assay                                    Bio-Rad Laboratories                                       4/29/2020    ELISA                                                    SARS-CoV-2 N protein                        Total Antibody
  New York SARS-CoV Microsphere Immunoassay for Antibody Detection      Wadsworth Center, New York State Department of Health      4/30/2020    Microsphere immunoassay                                  SARS-CoV-2 N protein                        Total Antibody
  Elecsys Anti-SARS-CoV-2                                               Roche Diagnostics                                          5/2/2020     Qualitative chemiluminescent immunoassay                 SARS-CoV-2 N protein                        Total Antibody
  Anti-SARS-CoV-2 ELISA (IgG)                                           EUROIMMUN US                                               5/4/2020     ELISA                                                    SARS-CoV-2 S protein                        IgG
  Atellica IM SARS-CoV-2 Total (COV2T)                                  Siemens Healthcare Diagnostics                             5/29/2020    Qualitative chemiluminescent microparticle immunoassay   SARS-CoV-2 S protein                        Total Antibody
  ADVIA Centaur SARS-CoV-2 Total (COV2T)                                Siemens Healthcare Diagnostics                             5/29/2020    Qualitative chemiluminescent microparticle immunoassay   SARS-CoV-2 S protein                        Total Antibody
  COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma)       Healgen Scientific                                         5/29/2020    Lateral flow immunoassay                                 SARS-CoV-2 S protein                        IgM, IgG
  RightSign COVID-19 IgG/IgM Rapid Test Cassette                        Hangzhou Biotest Biotech                                   6/4/2020     Lateral flow immunoassay                                 SARS-CoV-2 S protein RBD domain             IgM, IgG
  Vibrant COVID-19 Ab Assay                                             Vibrant America Clinical Labs                              6/4/2020     Qualitative chemiluminescent immunoassay                 SARS-CoV-2 S (S1, S2, RBD) and N proteins   IgM, IgG

Neutralizing Antibodies in Convalescent Patients
================================================

Neutralizing antibody from a convalescent patient is believed to block SARS-CoV-2 from entering into target cells. Lessons from the 2003 SARS-CoV-1 showed that the specific IgG antibodies and neutralizing antibodies were highly correlated, peaking at month 4 after the onset of disease and decreasing gradually thereafter. Long-lasting specific IgG and neutralizing antibody were reported at least 2 years and as long as 17 years after infection *(*[@jfaa100-B5]*)*. Because SARS-CoV-2 S protein is responsible for interacting with host receptors, antibody assays that target the S protein with titer results that correlate well with neutralizing assay would be of great value in assessing patients' immunity and potentially managing plasma donation from convalescent patients.

In summary, antibody assays of SARS-CoV-2 are mainly developed against the viral S or N protein and are available in multiple formats. Their clinical utility is for the identification of individuals with past exposure history to SARS-CoV-2 in the previous 2 weeks or longer. Presence of SARS-CoV-2 IgG potentially correlates with a virus-blocking effect (i.e., immunity), but further direct evidence needs to be collected.

Nonstandard abbreviations: S, spike; N, nucleocapsid; RBD, receptor-binding domain.

Author Contributions
====================

*All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.*

**Authors\' Disclosures or Potential Conflicts of Interest:** *No authors declared any potential conflicts of interest*.
